cGxP.wire https://validator.w3.org/feed/docs/rss2.html Zai Lab to Present First Clinical Data for ZL-1503 at ACAAI 2026 Invivyd Launches Phase 2 FLINTLOCK Trial of VYD2311 for Long COVID Quoin Pharmaceuticals Wins EMA Orphan Drug Designation for QRX003 Ocugen Licenses OCU400 Gene Therapy to Roots Pharmaceutical in MENA Entrada Therapeutics Reports Phase 1/2 DMD Trial Results for ENTR-601-45 Novastra Therapeutics to Present OAP-101 Phase 1 Data at ESMO 2026 Oorja Bio Initiates Phase 2 Trial of ORJ-001 for Lung Fibrosis Tenvie Therapeutics Doses First Subject in TNV313 Phase 1 Trial Agomab Doses First Patient in Phase 2b Ontunisertib Trial GT Medical Welcomes New GammaTile Center of Excellence Biomea Fusion Reports Phase 1 Results for Oral GLP-1 Drug BMF-650 Zealand Pharma and Generate Partner on AI-Designed Metabolic Drugs Rapalogix Reports Positive Clinical Results for Re-Q Serum TuHURA Wins U.S. Patent for Cancer Drug TBS-2025 Orum Therapeutics Doses First Patient in ORM-1153 Trial Zydus and Formycon Advance Keytruda Biosimilar FYB206 Rhythm Pharmaceuticals Launches IMCIVREE in Japan BioNTech Reports BNT113 Phase 3 Progression-Free Survival Results Triveni Bio Doses First Patient in TRIV-573 Phase 2 Trial Zimmer Biomet Extends THINK Surgical TMINI Distribution Deal Pulsenmore Appoints David Woods to Lead U.S. Growth IQVIA Selects Veeva Clinical Operations Applications Mirum to Discuss LIVMARLI Results in Phase 3 EXPAND Study Scinai Signs $5.1M Oncology Drug Manufacturing Agreement Jocasta and Diamond Target Cognitive Decline With New Drugs Akiram Shares First Phase 1 Data for Cancer Drug AKIR001 Mirum’s LIVMARLI Meets Phase 3 EXPAND Study Endpoint Rona and Roche Sign $1.16B Deal for ALK7 Obesity Therapy Accord BioPharma Launches FILKRI for Cancer Supportive Care! J&J Tremfya Sustains Crohn’s Remission Through Three Years Sironax Reaches 50% Enrollment in SIR4156 Obesity Trial Entera Bio Reports Stronger EB613 Bone-Building Effects Prelude and Lilly Partner to Test PRT13722 in Breast Cancer Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results TG Therapeutics Reports Five-Year BRIUMVI Comparison in MS Fujifilm Launches Synapse Pathology v3.0 With Expanded AI Stoke Therapeutics Presents STK-002 Data for Inherited Vision Loss Amphista Therapeutics Doses First Patient in AMX-883 Phase 1 Trial Tortugas Neuroscience Reports Positive Phase 2b Schizophrenia Results Savara to Present New Molgramostim Data at CHEST 2026 Galderma Reports New Research on Menopausal Skin Changes Mursla Bio Validates Tissue-Specific Liquid Biopsy Platform CervoMed Reports Positive NfL Biomarker Results With Neflamapimod Calluna Pharma Completes CAL101 Phase 2 IPF Trial Dosing Bristol Myers Squibb Reports Positive Phase 3 IPF Results ArkBio Advances AK0406 in US Phase II Influenza Prevention Trial E2 Secures Dual FDA Clearances for HLO PE Thrombectomy System Castle Biosciences Shows TissueCypher Detects Barrett’s Risk Immorta Bio Advances AI-Designed Senolytic Immunotherapy Johnson & Johnson Reports TREMFYA Fistula Remission Data